NEWS

"img

The Sermonix Blog

Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting

Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that it will present a poster on the [...]
Read more

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level experience to biopharmaceutical company conducting a Phase 2 clinical trial for the precision medicine treatment of metastatic breast cancer COLUMBUS, Ohio (April 23, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of [...]
Read more

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will present at the Boston Oncology Investor Conference. Dr. Portman will discuss the Phase 2 study of [...]
Read more

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a [...]
Read more

Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo model, and oncologists’ perceptions of ESR1 mutations and biomarker testing. COLUMBUS, Ohio, Nov. 14, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately […]
Read more

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Linical Accelovance Group will serve as research partner for study that compares lasofoxifene to fulvestrant. COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial for the treatment of [...]
Read more

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

Biotechnology company will globally develop and commercialize drug for treatment of advanced metastatic breast cancer. COLUMBUS, OH–(Marketwired – Oct 31, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million [...]
Read more

Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan

Accord allows Sermonix to globally develop and commercialize drug for treatment of advanced breast cancer COLUMBUS, OH–(Marketwired – Feb 28, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights to develop and [...]
Read more

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene For Breast Cancer Treatment

Women’s Oncology Pharmaceutical Company Also Raises More Than $2 Million in Preferred Seed Funding Round  COLUMBUS, OH, (December 7, 2016) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced that it signed a licensing agreement through which Sermonix will gain exclusive [...]
Read more

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal Serms at San Antonio Breast Cancer Symposium

 COLUMBUS, OH (November 28, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC). The Dec. [...]
Read more